mRNA vaccines have garnered considerable interest as a modern alternative to traditional vaccine methods due to several compelling advantages. They offer robust efficacy, facilitated by their ability to stimulate potent immune responses against targeted antigens. This attribute is particularly advantageous in rapidly developing vaccines against emerging infectious diseases, where swift production and deployment are critical. Moreover, mRNA vaccine technology holds promise for economical large-scale production, as it bypasses the need for cell culture systems used in traditional vaccine manufacturing. Despite these benefits, the initial adoption of mRNA vaccines was hindered by significant challenges. One major hurdle was the inherent instability of mRNA molecules, which are prone to degradation before they can effectively produce the desired proteins within cells. Additionally, efficiently delivering mRNA vaccines into cells posed another obstacle, as they needed to evade degradation in the bloodstream and reach the target cells intact to elicit a robust immune response. Recent advancements in mRNA vaccine technology have largely addressed these obstacles. The success of these vaccines has accelerated interest and investment in mRNA platforms for other infectious diseases and even cancer immunotherapy. This chapter explores these advancements in depth, providing insights into the mechanisms behind mRNA vaccines, recent clinical successes, and the remaining challenges that must be overcome to fully realize their therapeutic potential across diverse medical fields.